MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1515/cclm-2022-0516

Медицинская библиотека · Clinical chemistry and laboratory medicine · 2022

Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease.

Blennow Kaj, Stomrud Erik, Zetterberg Henrik, Borlinghaus Niels, Corradini Veronika, Manuilova Ekaterina, Müller-Hübner Laura, Quevenco Frances-Catherine, Rutz Sandra, Hansson Oskar

СтатьяПеревод пока не подготовлен

Аннотация

OBJECTIVES

Timely diagnosis of Alzheimer's disease (AD) is critical for appropriate treatment/patient management. Cerebrospinal fluid (CSF) biomarker analysis is often used to aid diagnosis. We assessed analytical performance of second-generation (Gen II) Elecsys® CSF immunoassays (Roche Diagnostics International Ltd), and adjusted existing cut-offs, to evaluate their potential utility in clinical routine.

METHODS

Analytical performance was assessed using CSF samples measured with Elecsys CSF Gen II immunoassays on cobas e analyzers. Aβ42 Gen I/Gen II immunoassay method comparisons were performed (Passing-Bablok regression). Cut-off values were adjusted using estimated bias in biomarker levels between BioFINDER protocol aliquots/Gen I immunoassays and Gen II protocol aliquots/immunoassays. Distribution of Gen II immunoassay values was evaluated in AD, mild cognitive impairment (MCI), and cognitively normal cohorts; percentage observations outside the measuring range were derived.

RESULTS

The Gen II immunoassays demonstrated good analytical performance, including repeatability, intermediate precision, lot-to-lot agreement (Pearson's r: ≥0.999), and platform agreement (Pearson's r: ≥0.995). Aβ42 Gen I/Gen II immunoassay measurements were strongly correlated (Pearson's r: 0.985-0.999). Aβ42 Gen II immunoassay cut-offs were adjusted to 1,030 and 800 ng/L, and pTau181/Aβ42 ratio cut-offs to 0.023 and 0.029, for Gen II and I protocols, respectively. No observations were below the lower limit of the measuring range; above the upper limit, there were none from the AD cohort, and 2.6 and 6.8% from the MCI and cognitively normal cohorts, respectively.

CONCLUSIONS

Our findings suggest that the Gen II immunoassays have potential utility in clinical routine to aid diagnosis of AD.

Для цитирования: Blennow Kaj, Stomrud Erik, Zetterberg Henrik, Borlinghaus Niels, Corradini Veronika, Manuilova Ekaterina, Müller-Hübner Laura, Quevenco Frances-Catherine, Rutz Sandra, Hansson Oskar. Second-generation Elecsys cerebrospinal fluid immunoassays aid diagnosis of early Alzheimer's disease.. Clinical chemistry and laboratory medicine. 2022. DOI: 10.1515/cclm-2022-0516.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.